Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis

被引：9

作者：

Pilkington, Hollie ^{[1
]}

Smith, Sarah ^{[1
]}

Roskell, Neil ^{[1
]}

Iannazzo, Sergio ^{[2
]}

机构：

[1] BresMed Hlth Solut, Manchester M2 1DH, Lancs, England

[2] Blueprint Med, CH-6300 Zug, Switzerland

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 13期

关键词：

advanced systemic mastocytosis; AdvSM; avapritinib; mast cells; matching-adjusted indirect comparison; midostaurin; ADJUSTED INDIRECT COMPARISONS; MAST-CELL DISORDERS; EFFICACY; NETWORK; SAFETY;

D O I：

10.2217/fon-2021-1509

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: This research aimed to compare the relative efficacy of avapritinib versus midostaurin for patients with advanced systemic mastocytosis. Method: A systematic literature review was performed to identify relevant evidence. Unanchored matching-adjusted indirect comparisons were conducted for overall survival (OS), overall response rate (ORR) and complete remission (CR). Results: The systematic literature review identified the clinical trials EXPLORER and PATHFINDER (investigating avapritinib) and D2201 and A2213 (investigating midostaurin). The avapritinib versus midostaurin adjusted hazard ratio for OS was 0.44 (95% CI: 0.25-0.76), and the adjusted odds ratios for ORR and CR were 4.06 (95% CI: 3.09-5.33) and 9.56 (95% CI: 0.97-93.81), respectively. Conclusion: The results suggest that avapritinib improves survival and response (ORR and CR) compared with midostaurin. Plain language summary Systemic mastocytosisis a rare blood disorder caused by the build-up of too many abnormal mast cells, a type of white blood cell, in the skin and organs. Patients with advanced systemic mastocytosis have a low life expectancy and limited treatment options. This research aimed to compare the effectiveness of two recent and innovative treatments (called avapritinib and midostaurin) in extending life expectancy and decreasing mast cells and organ damage. As avapritinib and midostaurin were not investigated in the same clinical studies, it was necessary to compare the two treatments using the results from studies of each individual treatment. The published evidence used to support this comparison was systematically searched for and consisted of four clinical studies: the EXPLORER and PATHFINDER studies (investigating avapritinib) and D2201 and A2213 studies (investigating midostaurin). An indirect comparison between the studies was made that adjusted for differences in key patient characteristics. The results suggest that compared with midostaurin, avapritinib has the potential to extend life expectancy and decrease disease burden.

引用

页码：1583 / 1594

页数：12

共 27 条

[1]

ClinicalTrials.gov, 2018, EFF SAF MID PAT AGGR

[2]

ClinicalTrials.gov, 2018, PHAS 2 MID AGGR SYST

[3]

ClinicalTrials.gov. (EXPLORER, 2021, STUD BLU 285 PAT ADV

[4]

ClinicalTrials.gov. (PATHFINDER, 2020, STUD EV EFF SAF AV B

[5] Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial [J].

DeAngelo, D. J. ;

George, T. I. ;

Linder, A. ;

Langford, C. ;

Perkins, C. ;

Ma, J. ;

Westervelt, P. ;

Merker, J. D. ;

Berube, C. ;

Coutre, S. ;

Liedtke, M. ;

Medeiros, B. ;

Sternberg, D. ;

Dutreix, C. ;

Ruffie, P-A ;

Corless, C. ;

Graubert, T. J. ;

Gotlib, J. .

LEUKEMIA, 2018, 32 (02) :470-478

[6] Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial [J].

DeAngelo, Daniel J. ;

Radia, Deepti H. ;

George, Tracy, I ;

Robinson, William A. ;

Quiery, Albert T. ;

Drummond, Mark W. ;

Bose, Prithviraj ;

Hexner, Elizabeth O. ;

Winton, Elliott F. ;

Horny, Hans-Peter ;

Tugnait, Meera ;

Schmidt-Kittler, Oleg ;

Evans, Erica K. ;

Lin, Hui-Min ;

Mar, Brenton G. ;

Verstovsek, Srdan ;

Deininger, Michael W. ;

Gotlib, Jason .

NATURE MEDICINE, 2021, 27 (12) :2183-+

[7]

European Medicines Agency: Committee for medicinal products for human use (CHMP), 2021, DRAFT AG M 21 24 JUN

[8] A precision therapy against cancers driven by KIT/PDGFRA mutations [J].

Evans, Erica K. ;

Gardino, Alexandra K. ;

Kim, Joseph L. ;

Hodous, Brian L. ;

Shutes, Adam ;

Davis, Alison ;

Zhu, Xing Julia ;

Schmidt-Kittler, Oleg ;

Wilson, Doug ;

Wilson, Kevin ;

DiPietro, Lucian ;

Zhang, Yulian ;

Brooijmans, Natasja ;

LaBranche, Timothy P. ;

Wozniak, Agnieszka ;

Gebreyohannes, Yemarshet K. ;

Schoffski, Patrick ;

Heinrich, Michael C. ;

DeAngelo, Daniel J. ;

Miller, Stephen ;

Wolf, Beni ;

Kohl, Nancy ;

Guzi, Timothy ;

Lydon, Nicholas ;

Boral, Andy ;

Lengauer, Christoph .

SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (414)

[9] KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders:: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients [J].

Garcia-Montero, Andres C. ;

Jara-Acevedo, Maria ;

Teodosio, Cristina ;

Luz Sanchez, Maria ;

Nunez, Rosa ;

Prados, Aranzazu ;

Aldanondo, Isabel ;

Sanchez, Laura ;

Dominguez, Mercedes ;

Botana, Luis M. ;

Sanchez-Jimenez, Francisca ;

Sotlar, Karl ;

Almeida, Julia ;

Escribano, Luis ;

Orfao, Alberto .

BLOOD, 2006, 108 (07) :2366-2372

[10] Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial [J].

Gotlib, Jason ;

Reiter, Andreas ;

Radia, Deepti H. ;

Deininger, Michael W. ;

George, Tracy, I ;

Panse, Jens ;

Vannucchi, Alessandro M. ;

Platzbecker, Uwe ;

Alvarez-Twose, Ivan ;

Mital, Andrzej ;

Hermine, Olivier ;

Dybedal, Ingunn ;

Hexner, Elizabeth O. ;

Hicks, Lisa K. ;

Span, Lambert ;

Mesa, Ruben ;

Bose, Prithviraj ;

Pettit, Kristen M. ;

Heaney, Mark L. ;

Oh, Stephen T. ;

Sen, Jayita ;

Lin, Hui-Min ;

Mar, Brenton G. ;

DeAngelo, Daniel J. .

NATURE MEDICINE, 2021, 27 (12) :2192-+

← 1 2 3 →